Ob­sE­va shares crater af­ter PhI­II fail; Al­lena Phar­ma un­veils pos­i­tive late-stage da­ta

→ Swiss biotech Ob­sE­va SA — fo­cused on treat­ments to im­prove women’s re­pro­duc­tive health — shared some dis­mal news to­day when it an­nounced that its Phase III clin­i­cal tri­al of no­la­si­ban in women un­der­go­ing em­bryo trans­fer fol­low­ing in-vit­ro fer­til­iza­tion failed to meet its pri­ma­ry end­point to in­crease the on­go­ing preg­nan­cy rate at 10 weeks. The com­pa­ny’s stock $OB­SV lost near­ly half in val­ue, trad­ing at $3.99 on Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER